Condition
Cutaneous Malignant Melanoma
Total Trials
5
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 3 (1)
Trial Status
Completed3
Active Not Recruiting1
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04620603Phase 1Active Not RecruitingPrimary
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
NCT06388252Not ApplicableEnrolling By InvitationPrimary
Electrochemotherapy Changes in Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Melanoma Patients
NCT01748448Phase 3CompletedPrimary
Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
NCT02308553Phase 1CompletedPrimary
Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma
NCT01482260CompletedPrimary
Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma
Showing all 5 trials